Unlock instant, AI-driven research and patent intelligence for your innovation.

Cyclodextrin-based polymers for therapeutics delivery

a technology of cyclodextrin and polymer, applied in the direction of extracellular fluid disorder, immunological disorder, metabolism disorder, etc., can solve the problems of toxic side effects, pharmacological profiles, drug delivery of some small molecule therapeutic agents, etc., and achieve the effect of facilitating endocytosis

Inactive Publication Date: 2011-11-17
CERULEAN PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention relates to novel compositions of polymer conjugates that comprise a polymer covalently attached to a therapeutic agent through a tether. The tether is cleavable under biological conditions to release the therapeutic agent. The polymer conjugates can be water-soluble and have enhanced selectivity in releasing the therapeutic agent. The selectivity-determining moiety promotes cleavage of the bond between the therapeutic agent and the polymer. The invention also provides methods for making the polymer conjugates and uses them for therapeutic purposes."

Problems solved by technology

Drug delivery of some small molecule therapeutic agents has been problematic due to their poor pharmacological profiles.
These therapeutic agents often have low aqueous solubility, their bioactive forms exist in equilibrium with an inactive form, or high systemic concentrations of the agents lead to toxic side-effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclodextrin-based polymers for therapeutics delivery
  • Cyclodextrin-based polymers for therapeutics delivery
  • Cyclodextrin-based polymers for therapeutics delivery

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of CDP-PEG-GFLG-MEDA-ETOP

Synthesis of FMOC-PEG-GFLG-MEDA

[0611]

[0612]Fmoc-PEG-aceticacid (5.7 g, 13 mmol), HBTU (4.9 g, 13 mmol), HOBT (2.0 g, 13 mmol), and DIPEA (3.4 g, 26 mmol) were dissolved in DMF (25 mL) GFLG-MEDA-Z (5.1 g, 8.8 mmol) was dissolved in DMF (13 mL) and DIPEA (3.7 g, 29 mmol) and added to the previous solution prepared. The reaction mixture was stirred for 1.5 h at room temperature. DMF was removed under reduced pressure and the obtained residue was dissolved in 200 mL CH2Cl2, the solution was washed twice with 0.1 N HCl (200 mL) and followed by washing with water (200 mL). It was then dried over MgSO4 and CH2Cl2 was removed under vacuum to yield crude product. It was then purified by flash column chromatography to yield white solid product, FMOC-PEG-GFLG-MEDA-Z (6.2 g, 72%).

[0613]FMOC-PEG-GFLG-MEDA-Z (3.0 g, 3.0 mmol) was dissolved in CH2Cl2 (60 mL) of 0.2 M 2-Bromo-1,3,2-benzodioxaborole (2.4 g, 12 mmol). The reaction mixture was stirred overnight at ro...

example 2

Synthesis of CDP-Carbamate-S—S-Etoposide

Synthesis of 4-nitrophenyl carbonate ester of etoposide

[0619]

[0620]In a dry 100 mL round bottom flask, etoposide (1.0 g, 1.7 mmol) and TEA (2.5 g, 25 mmol) were dissolved in anhydrous THF (35 mL) under argon. To that solution, 4-nitrophenyl chloroformate (0.39 g, 1.95 mmol) in anhydrous THF (15 mL) was added dropwise over 30 min. The reaction mixture was stirred for additional 2 h at RT. The mixture was filtered and concentrated under reduced pressure to yield yellow solid. The solid was purified by flash column chromatography to yield light yellow solid (0.75 g, 59%).

Synthesis of 4-pyridylthiol cysteamine carbamate of etoposide

[0621]

[0622]In a dry 25 mL round bottom flask, 4-nitrophenyl carbonate ester of etoposide (100 mg, 0.13 mmol), 4-pyridylthiol cysteamine hydrochloride (35 mg, 0.16 mmol), DIPEA (34 mg, 0.27 mmol) were dissolved in DMF (5 mL). The reaction mixture was stirred at room temperature for 15 h. DMF was removed under reduced pr...

example 3

Synthesis of CDP-EDA-Phosphoester-Etoposide

[0627]

[0628]In a 100 mL round bottom flask, etopophosphate (720 mg, 1.1 mmol), N,N′-diisopropylcarbodiimide (96 mg, 0.72 mmol), N-hydroxysuccinimide (83 mg, 0.72 mmol) and N,N-Diisopropylethylamine (140 mg, 2.3 mmol) were dissolved in anhydrous DMF (10 mL). The solution was stirred for 45 min at room temperature. EDA functionalized CDP (1.5 g, 0.60 mmol) and N,N-Diisopropylethylamine (160 mg, 2.3 mmol) were dissolved in anhydrous DMF (10 mL) on a separate 100 mL round bottom flask. This reaction mixture was added to the previous mixture at room temperature and stirred for 4 h at room temperature. The mixture was concentrated to 10 mL and precipitated out in ethyl acetate (500 mL). The polymer was dissolved in deionized water (150 mL) and it was dialyzed using 25K MWCO membrane (Spectra / Por 7) for 26 h. It was then filtered through 0.2 μm filters (Nalgene) and lyophilized to yield white solid (1.1 g, 73%). Loading of etoposide was determined...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
polydispersitiesaaaaaaaaaa
Login to View More

Abstract

Described herein is a cyclodextrin containing polymer conjugate.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 12 / 002,305, filed on Dec. 14, 2007, which claims priority to U.S. Ser. No. 60 / 897,096 filed on Jan. 24, 2007, and U.S. Ser. No. 61 / 002,752 filed on Nov. 9, 2007. The specifications of these applications are incorporated herein by reference in their entirety.BACKGROUND OF THE INVENTION[0002]Drug delivery of some small molecule therapeutic agents has been problematic due to their poor pharmacological profiles. These therapeutic agents often have low aqueous solubility, their bioactive forms exist in equilibrium with an inactive form, or high systemic concentrations of the agents lead to toxic side-effects. Some approaches to circumvent the problem of their delivery have been to conjugate the agent directly to a water-soluble polymer such as hydroxypropyl methacrylate (HPMA), polyethyleneglycol, and poly-L-glutamic acid. In some cases, such conjugates have been successful in solubilizing or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C08B30/18
CPCB82Y5/00A61K47/65A61K47/6939A61K47/6951A61K47/61A61P1/08A61P11/06A61P11/14A61P17/04A61P19/02A61P19/08A61P21/02A61P25/00A61P25/08A61P25/18A61P25/20A61P25/22A61P25/24A61P29/00A61P3/04A61P31/04A61P31/10A61P31/12A61P35/00A61P37/06A61P43/00A61P5/00A61P7/10A61P9/00A61P9/06A61P9/08A61P9/10A61P9/12
Inventor DAVIS, MARK E.HWANG, JUNGYEONKE, TIANYILIM, CHING-JOUSCHLUEP, THOMAS
Owner CERULEAN PHARMA